BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, December 25, 2025
See today's BioWorld
Home
» Young blood's elixir: Alkahest draws $38M from Grifols to battle CNS disorder
To read the full story,
subscribe
or
sign in
.
Young blood's elixir: Alkahest draws $38M from Grifols to battle CNS disorder
March 16, 2015
By
Michael Fitzhugh
Betting on the restorative power of young blood to reverse cognitive decline in Alzheimer's disease and other central nervous system disorders, Grifols SA is taking a 45 percent stake in Stanford University spinout Alkahest Inc.
BioWorld